UK Markets open in 4 hrs 9 mins

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
71.38-0.35 (-0.49%)
At close: 4:00PM EDT
Sign in to post a message.
  • A
    Anonymous
    FOSTER CITY, Calif.--(BUSINESS WIRE)--Sep. 22, 2021-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive results from a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a three-day course of Veklury® (remdesivir) for intravenous (IV) use for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression. This late-breaking data will be presented at the IDWeek 2021 virtual conference.
    In an analysis of 562 participants randomly assigned in a 1:1 ratio to receive Veklury or placebo, Veklury demonstrated a statistically significant 87% reduction in risk for the composite primary endpoint of COVID-19 related hospitalization or all-cause death by Day 28 (0.7% [2/279]) compared with placebo (5.3% [15/283]) p=0.008. Results also showed an 81% reduction in risk for the composite secondary endpoint of medical visits due to COVID-19 or all-cause death by Day 28 for participants treated with Veklury (1.6% [4/246]) compared with placebo (8.3% [21/252]) p=0.002. In the study, no deaths were observed in either arm by Day 28.
  • S
    SoapySmith
    Another Covid Variant is MU coming soon to a person near you !
    NIH and Eco Health Alliance should held accountable for Covid research at Wuhan Lab.
  • A
    Anonymous
    COVID-19 Research
    At IDWeek 2021, Gilead will present real-world analyses of Veklury, the antiviral standard of care for the treatment of hospitalized patients with COVID-19, to help inform real-time decision-making of clinicians and frontline healthcare workers. These data include a comparative retrospective analysis evaluating the impact of Veklury on mortality rates across the spectrum of baseline oxygen requirements. A second analysis, drawing on data from a large cohort study of U.S. hospitals, looks at the association of patients treated with Veklury and 30-day readmission rates. Further late-breaking data on Veklury in COVID-19 will also be presented at IDWeek.
  • b
    bill
    Once again, great news on Trodelvy and what does the market do?? Reject! It’s Remdesivir all over again, like Groundhog Day. Unbelievable! Please BOD’s….change the quarterback, ASAP! GLTAL!!
  • K
    Kjinman
    Not complaining as I am up about 10K here, but really thought we'd hear something by late Sept.

    BUYER on Day 1: Hey! We'd like to buy you guys out for $140 a share!
    GILD on Day 2: We had a day to mull it over and we except your offer!
    BUYER AND GILD on Day 3: Let's announce it to the world!

    I know it's a bit more complicated than this, but it doesn't take 6 or more months.

    Opportunity cost of not investing in JNCE about a month back has cost me a net of $50k so far, sheesh!!!!
  • J
    Jansen
    Gilead's Remdesivir reduced risk of hospitalization in high-risk patients
  • L
    Lenaverde
    Years ago (at least 20) GILD treated me mighty fine. Probably should have held it all these years.
    This go around I'm at the break even point on the stock price, but enjoy the dividend. Confident
    that GILD will be fine down the road. Holding.
  • S
    SoapySmith
    This document proves NIH had project at Wuhan Lab

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5708621/
    A large number of SARS-related coronaviruses (SARSr-CoV) have been detected in horseshoe bats since 2005 in different areas of China. However, these bat SARSr-CoVs show sequence differences from SARS coronavirus (SARS-CoV) in different genes (S, ORF8
    A large number of SARS-related coronaviruses (SARSr-CoV) have been detected in horseshoe bats since 2005 in different areas of China. However, these bat SARSr-CoVs show sequence differences from SARS coronavirus (SARS-CoV) in different genes (S, ORF8
    www.ncbi.nlm.nih.gov
  • j
    jerry
    Hey bag holders ready for the 60's this week?
  • L
    Lauren
    This stock will continue to go nowhere until the management team and CEO get replaced.
  • j
    jrward
    Looks like earnings release 10/28 after hours with a beat!! The beginning of the increase in share value going forward with a number of additional announcements coming from the pipeline so chill on blaming everything on the CEO! He was brought in to make a long term game plan and am confident he will end up a hero in the big picture!! This stock will double as it has in the past stay tuned and stay long!!!
  • G
    GERRY
    Positive news and it's the only red on my screen. LOL
  • S
    Sharbe
    Huge pre-market volume of a million shares. Most of it on upticks. Let's see what happens.
  • F
    Frank B
    As I have said often people on Wall Street for some reason hate Gilead. We have great news on a company we purchased , the best drugs on the market for HIV, cured hep c, have Kite for blood cancer and now seems to be targeting solid tumors and out if the blue we have a billion dollar drug that didn’t exist a year and half ago. Why isn’t the street pounding the table. Not to mention a great and safe dividend and possible takeover company
  • A
    Anonymous
    First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of Orally Administered GS-441524 in a Healthy Human Volunteer
    Actual Study Start Date :
    January 1, 2021
    Actual Primary Completion Date :
    May 1, 2021
    Actual Study Completion Date :
    August 1, 2021

    So maybe they will give us the results within a couple of months??
  • S
    Sharbe
    The chart looks really good. Draw the 50 day moving average, bar graph, and you will see a gradual up slope and it has used the 50 day as support. Classic. We very well could see $75 soon, maybe by month end or soon thereafter.
  • A
    Aaron
    People are starting to ask, where are the COVID-19 treatments? They are getting tired of the vaccine talk, which vaccine to take, how long does the vaccines last, vaccine to variants, long term side effects (if any), etc. It's time to get started on warp speed treatments.
  • B
    BioPharmaInvestor
    Are you aware that Gilead, NIH and MTNB are developing a safer oral LNC formulation of Remdesivir for all variants of Covid ? Are you also aware that Remdesivir has been shown to be effective for the Nipah Virus which has a death rate of up to 70% and has devastating, long-lasting side effects such as convulsions and personality changes ?
  • V
    ValueForAll
    $MTNB conversation
    I think it was already mentioned at least on $GILD forum once, but "sharbe" is just letters permutation of "basher". This is all you need to know about this account.
  • r
    real d
    NanoViricides' Remdesivir-Encapsulated COVID-19 Therapy Shows Encouraging Preclinical Safety Profile